1-bromo-7-propargyloxyheptane | 452340-33-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-bromo-7-propargyloxyheptane
• 英文别名: 3-[(7-bromoheptyl)oxy]prop-1-yne；7-bromoheptylprop-2-ynyl ether；1-Bromo-7-(prop-2-yn-1-yloxy)heptane；1-bromo-7-prop-2-ynoxyheptane
• CAS: 452340-33-9
• 化学式: C₁₀H₁₇BrO
• 分子量: 233.148
• InChiKey: JKXNGBZGOIOKLW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  12
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险类别：
  6.1
• 危险性防范说明：
  P201,P202,P261,P264,P270,P271,P280,P302+P352,P304+P340,P308+P313,P310,P330,P361,P403+P233,P405,P501
• 危险品运输编号：
  2810
• 危险性描述：
  H301,H311,H331,H341
• 包装等级：
  III

反应信息

• 作为反应物：
  描述：

  1-bromo-7-propargyloxyheptane 、 (5R)-5-(2,2-二甲基-4H-1,3-苯并二氧杂环己-6-基)-1,3-恶唑烷-2-酮 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 3.0h， 生成 (5R)-5-(2,2-dimethyl-4H-1,3-benzodioxin-6-yl)-3-[7-(prop-2-ynyloxy)heptyl]-1,3-oxazolidin-2-one
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Long-acting β₂ Adrenergic Receptor Agonists Incorporating Arylsulfonamide Groups

  摘要：

  A series of saligenin alkoxyalkylphenylsulfonamide beta(2) adrenoceptor agonists were prepared by reacting a protected saligenin oxazolidinone with alkynyloxyalkyl bromides, followed by Sonogashira reaction, hydrogenation, and deprotection. The meta-substituted primary sulfonamide was more potent than the para and the ortho-analogues. Primary sulfonamides were more potent than the secondary and tertiary analogues. The onset and duration of action in vitro of selected compounds was assessed on isolated superfused guinea pig trachea. Sulfonamide 29b had the best profile of potency, selectivity, onset, and duration of action on both guinea pig trachea and human bronchus. Furthermore, 29b was found to have low oral bioavailability in rat and dog and also to have long duration of action in an in vivo model of bronchodilation. Crystalline salts of 29b were identified that had suitable properties for inhaled administration. A proposed binding mode for 29b to the beta(2)-receptor is presented.

  DOI：

  10.1021/jm801016j
• 作为产物：
  描述：

  1,7-二溴庚烷 、 2-丙炔-1-醇 在 四丁基硫酸氢铵 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 72.0h， 生成 1-bromo-7-propargyloxyheptane
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of Long-acting β₂ Adrenergic Receptor Agonists Incorporating Arylsulfonamide Groups

  摘要：

  A series of saligenin alkoxyalkylphenylsulfonamide beta(2) adrenoceptor agonists were prepared by reacting a protected saligenin oxazolidinone with alkynyloxyalkyl bromides, followed by Sonogashira reaction, hydrogenation, and deprotection. The meta-substituted primary sulfonamide was more potent than the para and the ortho-analogues. Primary sulfonamides were more potent than the secondary and tertiary analogues. The onset and duration of action in vitro of selected compounds was assessed on isolated superfused guinea pig trachea. Sulfonamide 29b had the best profile of potency, selectivity, onset, and duration of action on both guinea pig trachea and human bronchus. Furthermore, 29b was found to have low oral bioavailability in rat and dog and also to have long duration of action in an in vivo model of bronchodilation. Crystalline salts of 29b were identified that had suitable properties for inhaled administration. A proposed binding mode for 29b to the beta(2)-receptor is presented.

  DOI：

  10.1021/jm801016j

文献信息

• The Antiadhesive Strategy in Crohn′s Disease: Orally Active Mannosides to Decolonize Pathogenic<i>Escherichia coli</i>from the Gut
  作者：Dimitri Alvarez Dorta、Adeline Sivignon、Thibaut Chalopin、Tetiana I. Dumych、Goedele Roos、Rostyslav O. Bilyy、David Deniaud、Eva-Maria Krammer、Jérome de Ruyck、Marc F. Lensink、Julie Bouckaert、Nicolas Barnich、Sébastien G. Gouin

  DOI：10.1002/cbic.201600018

  日期：2016.5.17

  Ready for take off? Adherent‐invasive E. coli (AIEC) were shown to promote the inflammation of the intestinal mucosa of patients with Crohn′s disease (CD). We have designed a small library of AIEC antiadhesives, one of which could decolonize AIEC from the gut of a transgenic CD mouse model. These might open new perspectives in the treatment of CD.

  准备起飞？粘附侵袭性大肠杆菌（AIEC）被证明可促进克罗恩病（CD）患者肠道粘膜的炎症。我们设计了一个小的AIEC抗粘剂库，其中一个库可以使AIEC从转基因CD小鼠模型的肠道中非克隆化。这些可能会为CD的治疗开辟新的视野。
• [EN] PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES<br/>[FR] DERIVES DE PHENETHANOLAMINE POUR TRAITER DES MALADIES RESPIRATOIRES
  申请人：GLAXO GROUP LTD

  公开号：WO2003072539A1

  公开（公告）日：2003-09-04

  The present invention relates to novel compounds of formula (I),to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

  本发明涉及式（I）的新化合物，涉及其制备方法，含有它们的药物组合物，以及它们在治疗中的应用，特别是在预防和治疗呼吸道疾病中的应用。
• [EN] DETECTION OF PATHOGENIC BACTERIA BY CHEMICALLY FUNCTIONALIZED CELLULOSE<br/>[FR] DÉTECTION DE BACTÉRIES PATHOGÈNES PAR CELLULOSE FONCTIONNALISÉE CHIMIQUEMENT
  申请人：CENTRE NAT RECH SCIENT

  公开号：WO2020260445A1

  公开（公告）日：2020-12-30

  The present invention concerns the rapid and selective detection of pathogenic bacteria expressing a lectin-type adhesin in a biological environment using a cellulose support functionalized with a ligand of a lectin-type adhesin, and its use for the diagnostic of infection with pathogenic bacteria expressing a lectin- type adhesin, for example in the context of Crohn's disease or in urinary tract infections.

  本发明涉及在生物环境中利用功能化的纤维素支持物检测表达凝集素型粘附素的病原细菌的快速和选择性方法，以及其用于诊断感染表达凝集素型粘附素的病原细菌，例如在克罗恩病或尿路感染的背景下。
• Phenethanolamine derivatives for treatment of respiratory diseases
  申请人：Blake Keith

  公开号：US20050209338A1

  公开（公告）日：2005-09-22

  The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

  本发明涉及式（I）的新化合物，以及制造它们的方法，包含它们的制药组合物，以及它们在治疗中的应用，特别是在预防和治疗呼吸系统疾病方面的应用。
• PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES
  申请人：BIGGADIKE Keith

  公开号：US20060287286A1

  公开（公告）日：2006-12-21

  The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

  本发明涉及式(I)的新化合物、其制备方法、含有它们的制药组合物以及它们在治疗中的应用，特别是它们在预防和治疗呼吸系统疾病中的应用。